Head-to-head · WeighScore
9amHealth vs Gala Health
By GLP-1 ScorecardUpdated
Score comparison
Gala Health has the higher recorded score — 82.9/100 to 71.3/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | 9amHealth | Gala Health |
|---|---|---|
| WeighScore | 71.3/100 | 82.9/100 |
| Grade | C | B− |
| Site position | #103 | #12 |
| Semaglutide | Not disclosed (brand-name; current medication quote required) | From $129/mo (campaign; plan pages conflict—confirm billing term) |
| Tirzepatide | Not disclosed | From $179/mo (campaign; yearly and three-month offers conflict—confirm term) |
| Coverage | Coverage not published | Coverage wording differs: all 50 on homepage, most U.S. states in campaign |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #103 · C
Strengths
- Care team includes physicians, pharmacists and registered dietitians
- Individual program describes continuing medication management, follow-up and nutrition support
- Branded GLP-1 options are considered alongside medical history, tests and insurance coverage
- Home blood draw where available or a patient service center, with care-team review
- Separate individual, employer and health-plan programs offer different access routes
What to consider
- Current care and medication charges need a selected written quote; older campaign prices conflict
- The advertised $199 Wegovy introduction expired June 30, 2025
- Care, medication and lab costs depend on the selected program and benefits; obtain an itemized quote
- Clinical eligibility and the applicable benefit formulary determine prescription access
- The reviewed public pages do not establish current cancellation, refund or state-by-state terms
Site position #12 · B−
Strengths
- Campaign advertises $129 semaglutide and $179 tirzepatide with medication and telehealth visits included if prescribed
- Brand-name Ozempic path and broader menopause/HRT services listed
- Terms identify clinical practice networks; actual clinician and pharmacy assignment still need checking
What to consider
- Yearly, three-month and no-contract campaign presentations differ; do not assume an annual upfront charge or flat month-to-month terms
- Cancel at least 72 hours before renewal; ordinary cancellation does not produce a refund
- Medical-disqualification refund wording differs between full-refund and remaining/current-cycle provisions
- Dispensing pharmacy not identified for an individual order; oral option is a waitlist, not a current offer
Featured provider
Gala Health
Gala Health scores 82.9/100 (B−). Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.